Alternatives to CRISPR Therapeutics

Scalable, one-time curative in-vivo gene editing therapies.

Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.

A clinical-stage biotechnology company developing in vivo gene editing therapies.

Developing disease-responsive advanced therapies through programmable gene control technology.

Global supplier of life science research tools, including antibodies, reagents, and assays.

A biotechnology company developing precision genetic medicines through base editing technology to treat a broad range of diseases.

Developing magnetic cell delivery platform for advanced therapies.

Arrakis Bio is developing novel therapeutics for cancer and other diseases using a proprietary gene editing platform.

Developing genetic medicines and cell therapies for severe diseases using proprietary CRISPR OMNI technology.

A clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.

A clinical-stage genome editing company developing novel therapies using CRISPR/Cas9 technology for severe diseases.

Omega Therapeutics is developing a new class of programmable medicines called Epigenomic Controllers.

Gene therapy company developing transformative treatments for severe genetic diseases.

Developing polymer-based nanoparticles for targeted gene therapy delivery.

Develops advanced gene editing and cell therapy solutions for rare genetic diseases.

Biotechnology company developing cell and gene therapies for serious diseases.

VI Therapeutics is developing novel therapies for rare genetic diseases.

Developing gene editing therapies for rare genetic diseases.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

Clinical-stage biotech company developing transformative cytokine therapies.

Advancing anti-PACAP therapies for the prevention of migraine and other headache disorders.

Biotechnology company developing new medicines for Parkinson's disease and other neurological disorders.

Biotechnology company developing and commercializing cell therapies for cancer treatment.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Developing novel therapeutics to restore gut lymphatic function.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Biopharmaceutical company developing and commercializing CNS disease treatments.

Enzyme-based technology to break down alcohol in the stomach.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A global leader in clinical pharmacology and bioanalytical sciences.

BreezeBio is a genetic medicine company developing a pipeline of precision therapeutics.

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

Accelerating patient access to evidence-based innovation in mental health.

A biotechnology company developing genetic therapies for rare disorders.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

Developing TCR-mimetic antibody therapies to treat cancer by targeting peptide-loaded major histocompatibility complexes.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

Engineering scalable gene therapies for broader patient populations.

Biotechnology company advancing novel therapeutics using its proprietary LEADS drug discovery platform.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

Developing highly targeted, small molecule medicines.

AI-powered antibody discovery platform.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

Pioneering vision restoration therapies for severe retinal degenerations.

Developing oral small molecule medicines for immunological and chronic diseases.

A pharmaceutical company focused on developing long-acting injectable medicines.